News for 'sun-pharma'

Sensex falls 344 pts amid profit-taking, foreign fund outflows

Sensex falls 344 pts amid profit-taking, foreign fund outflows

Rediff.com24 Oct 2025

Among Sensex firms, Hindustan Unilever dropped the most by 3.20 per cent. UltraTech Cement, Kotak Mahindra Bank, Adani Ports, Titan, HDFC Bank and Axis Bank were also among the laggards. However, Bharti Airtel, ICICI Bank, Bharat Electronics and Sun Pharma were among the gainers.

Big leap for Sun Pharma, Sunshine for Ranbaxy

Big leap for Sun Pharma, Sunshine for Ranbaxy

Rediff.com8 Apr 2014

Ranbaxy's troubled plants in India could see a turnaround as Sun Pharma has experience in doing so.

US drug regulator raps Sun Pharma unit

US drug regulator raps Sun Pharma unit

Rediff.com5 Nov 2008

The US subsidiary of Sun Pharmaceuticals, Caraco Pharmaceutical Laboratories, has received a warning letter from the Food and Drug Administration.

Sensex, Nifty dive nearly 1% as HDFC Bank, RIL drag

Sensex, Nifty dive nearly 1% as HDFC Bank, RIL drag

Rediff.com22 Aug 2025

From the Sensex pack, Asian Paints, UltraTech Cement, Tata Steel, ITC, HCL Tech, Kotak Mahindra Bank, Adani Ports, Tata Consultancy Services, HDFC Bank and Tech Mahindra were among the major laggards. However, Mahindra & Mahindra, Maruti, Bharat Electronics and Sun Pharma were among the gainers.

What lies ahead for Sun Pharma post Ranbaxy merger approval

What lies ahead for Sun Pharma post Ranbaxy merger approval

Rediff.com31 Mar 2015

Sun Pharmaceutical's acquisition of Ranbaxy has received final approvals.

Sun Pharma recalls over 5,000 bottles of eye medicine in the US

Sun Pharma recalls over 5,000 bottles of eye medicine in the US

Rediff.com8 Mar 2015

The recall was initiated by the company on January 21

Sun Pharma arm settles case with Biofrontera, to get $22.5 mn

Sun Pharma arm settles case with Biofrontera, to get $22.5 mn

Rediff.com30 Nov 2021

Sun Pharmaceutical Industries on Tuesday said its arm DUSA Pharmaceuticals Inc has reached settlement with Biofrontera to resolve a litigation over misappropriation of trade secrets and unfair practice, following which DUSA will receive $22.5 million (nearly Rs 170 crore). In 2018, DUSA Pharmaceuticals had filed a suit at the US District Court of Massachusetts against Biofrontera Inc Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG (together known as Biofrontera) alleging "misappropriation of trade secrets, tortious interference of contract and unfair trade practices".

Sensex jumps 555 pts on value buying, strong GDP data

Sensex jumps 555 pts on value buying, strong GDP data

Rediff.com1 Sep 2025

Among Sensex firms, Mahindra & Mahindra, Tata Motors, Trent, Eternal, Asian Paints and Infosys were the major gainers. However, Sun Pharma, ITC, Hindustan Unilever and Titan were among the laggards.

Sensex climbs 329 points on global markets' rally

Sensex climbs 329 points on global markets' rally

Rediff.com25 Aug 2025

From the Sensex firms, Infosys, Tata Consultancy Services, HCL Tech, Tech Mahindra, Tata Motors, Sun Pharma, Maruti and Titan were among the major gainers. Bharat Electronics, Asian Paints, Bharti Airtel and ICICI Bank were among the laggards.

Sun Pharma in talks to buy Meda for $5-$6 billion

Sun Pharma in talks to buy Meda for $5-$6 billion

Rediff.com31 May 2013

Acquisition to boost its generics business in developed markets.

Sun Pharma, Mahindras in India's top-10 club

Sun Pharma, Mahindras in India's top-10 club

Rediff.com31 Mar 2013

These two are now among India's most valuable business houses, ahead of older and more diversified groups, such as the Bajaj, OP Jindal, Anil Ambani, UB, Godrej and Hinduja.

Integration challenges: Sun Pharma's next hurdle

Integration challenges: Sun Pharma's next hurdle

Rediff.com23 Apr 2015

The challenge of merging Ranbaxy into the company has not been factored in.

Sensex climbs 398 points on buying in RIL, IT counters

Sensex climbs 398 points on buying in RIL, IT counters

Rediff.com9 Oct 2025

Among Sensex firms, Tata Steel, HCL Tech, UltraTech Cement, Bharat Electronics, Sun Pharma and Tata Consultancy Services were the major gainers. However, Axis Bank, Titan, Maruti and Tata Motors were among the laggards.

Sun Pharma gets USFDA nod for epilepsy drug

Sun Pharma gets USFDA nod for epilepsy drug

Rediff.com17 Jun 2010

Drug maker Sun Pharmaceutical Industries on Thursday said it has received the US health regulator's nod for marketing a generic version of the Keppra injection, used for treating epilepsy, in the American market.

Sensex, Nifty tank nearly 1% on selling in pharma, IT shares

Sensex, Nifty tank nearly 1% on selling in pharma, IT shares

Rediff.com26 Sep 2025

Most pharma shares dropped, dragging the BSE Healthcare index down by 2.14 per cent after Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1. Wockhardt shares tanked 9.4 per cent.

Sun Pharma's m-cap sinks by Rs 8,736 crore in just one day

Sun Pharma's m-cap sinks by Rs 8,736 crore in just one day

Rediff.com18 Jan 2019

The stock was the worst hit among the blue-chips on both BSE and NSE.

Despite profit-booking, Sensex, Nifty end higher

Despite profit-booking, Sensex, Nifty end higher

Rediff.com8 Sep 2025

Among Sensex firms, Tata Motors rose the most by 3.97 per cent. Mahindra & Mahindra jumped by 3.96 per cent. Maruti, Adani Ports, Bajaj Finance and UltraTech Cement were also among the gainers. However, Trent declined 3.81 per cent. Asian Paints, HCL Tech, Tech Mahindra, L&T, TCS, Power Grid and Sun Pharma were also among the laggards.

Bulls prowl D-Street: Sensex jumps 716 points

Bulls prowl D-Street: Sensex jumps 716 points

Rediff.com1 Oct 2025

From the Sensex firms, Tata Motors jumped the most by 5.54 per cent, followed by Kotak Mahindra Bank, Trent, Sun Pharma, Axis Bank, and ICICI Bank. However, Bajaj Finance, State Bank of India, UltraTech Cement and Tata Steel were among the laggards.

Sun Pharma: Needs more of the US pie

Sun Pharma: Needs more of the US pie

Rediff.com31 Mar 2009

The Rs 3,290 crore (Rs 32.9 billion) Sun plans to sell Topamax in four strengths ranging from 25mg to 200mg, the combined market for which is estimated to be $2.5 billion. There is, of course, no litigation with the patent holder OrthoMcneill Janssen. The US market, which brings in about 40 per cent of Sun's consolidated sales and has driven revenues in the past few year could lose momentum.

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

Rediff.com12 Aug 2025

If pharmaceutical exports from India to the US come under a 25 per cent tariff bracket, the impact on earnings before interest, tax, depreciation and amortisation (Ebitda) could be around 5 per cent, felt analysts. This is after assuming that about 75 per cent of the tariff would be passed on.

HC lifts stay on Sun Pharma's $3.2 billion Ranbaxy takeover

HC lifts stay on Sun Pharma's $3.2 billion Ranbaxy takeover

Rediff.com24 May 2014

Both companies can now complete the deal.

Sensex climbs 124 points; Nifty ends above 25K

Sensex climbs 124 points; Nifty ends above 25K

Rediff.com11 Sep 2025

Among Sensex firms, NTPC, Axis Bank, Power Grid, Bharti Airtel, Eternal and Sun Pharma were the major gainers. However, Infosys, Titan, UltraTech Cement and Hindustan Unilever were among the laggards.

Sun Pharma, Cipla get tentative nod for drug

Sun Pharma, Cipla get tentative nod for drug

Rediff.com23 May 2006

Sun Pharma Ltd has received tentative approval for cancer drug Ondansetron from US Food and Drug Administration.

Sun Pharma makes open offer for Zenotech stake

Sun Pharma makes open offer for Zenotech stake

Rediff.com13 Apr 2014

Sun Pharma has evinced its interest in buying Hyderabad-based biotech company Zenotech Laboratories, through an open offer to buy 28.1 per cent worth Rs 18.41 crore ($3 million).

Sun Pharma to invest Rs 450 cr for expansion

Sun Pharma to invest Rs 450 cr for expansion

Rediff.com30 May 2011

Israel-based Taro pharmaceutical industries became Sun Pharma's subsidiary on September 20, 2010.

Sensex, Nifty end in red on concerns over US tariff

Sensex, Nifty end in red on concerns over US tariff

Rediff.com31 Jul 2025

Equity benchmark indices Sensex and Nifty ended lower on Thursday after US President Donald Trump announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1 and an unspecified penalty for buying Russian crude oil and military equipment.

Sensex pares losses, ends up 64 points

Sensex pares losses, ends up 64 points

Rediff.com16 Jul 2025

Among Sensex firms, Mahindra & Mahindra, Tech Mahindra, State Bank of India, Infosys, Adani Ports and ITC were the major gainers. However, Eternal, Sun Pharma, Tata Steel, Tata Motors, Bajaj Finance and Bharat Electronics were among the major laggards.

Sensex ends down 119 points on profit-taking in IT, auto shares

Sensex ends down 119 points on profit-taking in IT, auto shares

Rediff.com15 Sep 2025

Among Sensex firms, Mahindra & Mahindra, Asian Paints, Infosys, Titan, Sun Pharma, Tata Consultancy Services, Tech Mahindra and Power Grid were the major laggards. However, Bajaj Finance, Eternal, UltraTech Cement and Reliance Industries were among the gainers.

Stock markets end lower amid Israel-Iran conflict, rising crude oil prices

Stock markets end lower amid Israel-Iran conflict, rising crude oil prices

Rediff.com17 Jun 2025

From the Sensex pack, Sun Pharma, Eternal, Tata Motors, Bajaj Finance, IndusInd Bank and Bajaj Finserv were among the major laggards. In contrast, Tech Mahindra, Infosys, Asian Paints and Maruti were among the gainers.

Sun Pharma unit recalls mutiple lots of capsules from US

Sun Pharma unit recalls mutiple lots of capsules from US

Rediff.com15 Aug 2014

The recalled drug bottles were distributed by Caraco Pharmaceutical Laboratories, Ltd in the US while manufactured in India by Sun Pharmaceutical Industries Ltd.

Sun Pharma's growth pill: Specialising in specialty and scaling in India

Sun Pharma's growth pill: Specialising in specialty and scaling in India

Rediff.com25 Mar 2024

Traction for its specialty portfolio, a strong showing in the domestic market, and better regulatory compliance are positives for the country's largest pharmaceutical (pharma) company, Sun Pharmaceutical Industries. Given the triggers, some brokerages have increased their earnings per share estimates and target price for 2024-25 (FY25). This should sustain the momentum for the stock, which has been one of the major pharma gainers in 2023-24 (FY24), rising 57 per cent. It is currently trading at Rs 1,547 per share.

As shares plunge to 5-year low, Sun Pharma promoters poorer by Rs 12,660 crore in 10 days

As shares plunge to 5-year low, Sun Pharma promoters poorer by Rs 12,660 crore in 10 days

Rediff.com6 Dec 2018

Sun Pharma's market capitalisation stood at Rs 100,050 crore on December 5, with its share price closing at Rs 417 a piece - lowest since March 2013.

Why Sun Pharma stock will remain under pressure

Why Sun Pharma stock will remain under pressure

Rediff.com24 Dec 2019

The weakness in the stock was because of inspections by the American drug regulator at its Halol plant in Gujarat which resulted in eight observations, as well as a downward revision of speciality drug payoffs.

Sensex tanks 721 pts dragged by Bajaj Finance, foreign fund outflows

Sensex tanks 721 pts dragged by Bajaj Finance, foreign fund outflows

Rediff.com25 Jul 2025

Stock markets declined for the second day in a row on Friday, with the Sensex tumbling 721 points due to heavy selling in financial, IT and oil & gas shares amid persistent foreign fund outflows.

Sun Pharma rejects Taro's offer of $15 per share

Sun Pharma rejects Taro's offer of $15 per share

Rediff.com8 Jan 2009

Sun had rejected Taro's offer of conducting a shareholder referendum at any price of its (Sun's) choosing to settle the issue, besides offering other options, saying it was an attempt to sidestep from the real issues.

Blue-chip stocks drag Sensex down by 542 points

Blue-chip stocks drag Sensex down by 542 points

Rediff.com24 Jul 2025

From the Sensex firms, Trent, Tech Mahindra, Bajaj Finserv, Reliance Industries, Infosys, Kotak Mahindra Bank, HCL Technologies, and NTPC were among the biggest laggards. However, Eternal, Tata Motors, Sun Pharma, Tata Steel, and Titan were the gainers.

Ranbaxy woes continue to dog Sun Pharma

Ranbaxy woes continue to dog Sun Pharma

Rediff.com29 Oct 2015

The recalled drugs were manufactured and distributed in the US by Ohm Laboratories.

Sensex surges over 769 pts as FMCG, power shares gain

Sensex surges over 769 pts as FMCG, power shares gain

Rediff.com23 May 2025

From the Sensex firms, Eternal, Power Grid, ITC, Bajaj Finserv, Nestle, Axis Bank, Kotak Mahindra Bank and Adani Ports were among the biggest gainers. Sun Pharma was the only laggard, declining nearly 2 per cent.

Sensex, Nifty rebound nearly 1% on value buying

Sensex, Nifty rebound nearly 1% on value buying

Rediff.com16 Jun 2025

Among 30 Sensex firms, UltraTech Cement, Tech Mahindra, HCL Tech, Tata Consultancy Services, Eternal, Asian Paints, Tata Steel and Kotak Mahindra Bank were among the biggest gainers. Tata Motors, Adani Ports and Sun Pharma were the laggards.

Sensex tanks 586 points on global sell-off

Sensex tanks 586 points on global sell-off

Rediff.com1 Aug 2025

Tata Steel, Maruti, Tata Motors, Infosys, Bharti Airtel and Tech Mahindra were also among the laggards. However, Trent, Asian Paints, Hindustan Unilever, ITC, Kotak Mahindra Bank, and Reliance Industries were the gainers.